Sartorius Stedim Biotech Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Rene Faber

İcra Kurulu Başkanı

€790.0k

Toplam tazminat

CEO maaş yüzdesi	68.4%
CEO görev süresi	1.7yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	8.4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Rene Faber'un ücretlendirmesi Sartorius Stedim Biotech'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	€161m
Jun 30 2024	n/a	n/a	€170m
Mar 31 2024	n/a	n/a	€255m
Dec 31 2023	€790k	€540k	€310m
Sep 30 2023	n/a	n/a	€460m
Jun 30 2023	n/a	n/a	€635m
Mar 31 2023	n/a	n/a	€717m
Dec 31 2022	€578k	€288k	€876m
Sep 30 2022	n/a	n/a	€681m
Jun 30 2022	n/a	n/a	€625m
Mar 31 2022	n/a	n/a	€559m
Dec 31 2021	€901k	€396k	€414m
Sep 30 2021	n/a	n/a	€523m
Jun 30 2021	n/a	n/a	€469m
Mar 31 2021	n/a	n/a	€398m
Dec 31 2020	€742k	€396k	€336m
Sep 30 2020	n/a	n/a	€299m
Jun 30 2020	n/a	n/a	€255m
Mar 31 2020	n/a	n/a	€254m
Dec 31 2019	€784k	€425k	€235m

Tazminat ve Piyasa: Rene 'nin toplam tazminatı ($USD 831.67K ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 5.70M ).

Tazminat ve Kazançlar: Rene şirketinin tazminatı %20'den fazla artarken, şirketin kazancı geçen yıl %20'den fazla düştü.

CEO

Rene Faber (49 yo)

1.7yrs

Görev süresi

€790,000

Tazminat

Dr. Rene Faber serves as Head of Bioprocess Solutions Division and Member of the Executive Board at Sartorius Aktiengesellschaft since January 01, 2019. He serves as Chief Executive Officer at Sartorius St...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Rene Faber	CEO & DIrector	5.7yrs	€790.00k	Veri yok
Joachim Kreuzburg	Non-Executive & Non-Independent Chairman	17.4yrs	€693.15k	0.000010% € 1.6k
Lothar Kappich	Director	7.2yrs	€84.00k	0% € 0
Henri Riey	Director	17.4yrs	€56.00k	0.000010% € 1.6k
Pascale Boissel	Independent Director	5.7yrs	€93.00k	0% € 0
Anne-Marie Graffin	Lead Independent Director	9.6yrs	€91.00k	0.000010% € 1.6k
Susan Dexter	Independent Director	9.6yrs	€84.00k	0.000010% € 1.6k
Romaine Fernandes	Employee Representative Non - Executive Director	1.1yrs	Veri yok	0% € 0

8.4yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0RG8 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.4 yıldır).

Sartorius Stedim Biotech Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 27, 2023

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Sartorius Stedim Biotech S.A. to Report Fiscal Year 2024 Results on Jan 28, 2025

Third quarter 2024 earnings released: EPS: €0.26 (vs €0.28 in 3Q 2023)

Second quarter 2024 earnings released: €0.011 loss per share (vs €1.44 profit in 2Q 2023)

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 17%

First quarter 2024 earnings released: EPS: €0.58 (vs €1.21 in 1Q 2023)

Upcoming dividend of €0.69 per share

Dividend of €0.69 announced

New minor risk - Profit margin trend

Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion.

Sartorius Stedim Biotech S.A. to Report Nine Months, 2024 Results on Oct 17, 2024

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 15%

New major risk - Financial position

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 18%

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: €1.44 (vs €2.33 in 2Q 2022)

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 15%

Investor sentiment deteriorates as stock falls 15%

First quarter 2023 earnings released: EPS: €1.21 (vs €2.93 in 1Q 2022)

Upcoming dividend of €1.44 per share at 0.5% yield

Full year 2022 earnings released: EPS: €9.51 (vs €4.50 in FY 2021)

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2023

Sartorius Stedim Biotech S.A. to Report Fiscal Year 2022 Results on Jan 26, 2023

Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 27, 2023

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: €2.22 (vs €1.60 in 3Q 2021)

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2022

Investor sentiment deteriorated over the past week

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire Albumedix Ltd. from private investors for approximately £420 million.

Second quarter 2022 earnings released: EPS: €2.33 (vs €1.61 in 2Q 2021)

First quarter 2022 earnings released: EPS: €2.93 (vs €1.24 in 1Q 2021)

Less than half of directors are independent

First quarter 2022 earnings released: EPS: €2.93 (vs €1.24 in 1Q 2021)

Sartorius Stedim Biotech S.A. Confirms Earnings Guidance for the Year 2022

Sartorius Stedim Biotech S.A. Approves Dividend for the Fiscal Year 2021

Upcoming dividend of €1.26 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sartorius Stedim Biotech S.A. Updates Earnings Guidance for the Year 2022

Sartorius Stedim Biotech S.A. Recommends Dividend

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of chromatography equipment division from Novasep Holding SAS.

Sartorius Stedim Biotech Provides Earnings Guidance for the Full Year 2022

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS €1.60 (vs €1.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS €1.56 (vs €0.73 in 2Q 2020)

Sartorius Stedim Biotech S.A. Raises Forecast for the Full Year 2021

First quarter 2021 earnings released: EPS €1.24 (vs €0.81 in 1Q 2020)

Sartorius Stedim Biotech Raises Consolidated Sales Guidance for 2021

Sartorius Stedim Biotech Increases Earnings Guidance for 2021

Full year 2020 earnings released: EPS €3.88 (vs €2.54 in FY 2019)

Revenue misses expectations

New 90-day high: €366

Sartorius Stedim Biotech S.A. to Report Nine Months, 2021 Results on Oct 20, 2021

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) signed an agreement to acquire chromatography equipment division from Novasep Holding SAS.

New 90-day high: €329

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of BIA Separations d.o.o.

Third-quarter earnings released: Revenue beats expectations

Third quarter earnings released

Sartorius Stedim Biotech S.A. to Report Q1, 2021 Results on Apr 21, 2021

New 90-day high: €309

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire BIA Separations d.o.o. for ?€360 million.

New 90-day high - €280

Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of certain businesses from Danaher Corporation (NYSE:DHR).

New 90-day high - €271

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi